Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07864792
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8

Eligibility Criteria

Sex
FEMALE
Age
60 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Sham Intervention — PROCEDURE
    Receive sham tDCS
  • Survey Administration — OTHER
    Ancillary studies
  • Transcranial Direct Current Stimulation — DEVICE
    Receive tDCS

Study Details

This clinical trial tests the effect of transcranial direct current stimulation (tDCS) to improve gait in older breast cancer survivors who received taxane and/or platinum chemotherapy. Chemotherapy, especially taxane or platinum therapy, can cause damage to the to the nerves resulting in numbness, tingling and pain, which can cause difficulty walking. It can also cause cognitive dysfunction which may effect gait. TDCS is a non-invasive brain stimulation device which uses a very mild electrical current applied to the scalp to temporarily stimulate a specific area of the brain involved in thinking and movement which may improve walking, particularly while doing two things at once. TDCS may be effective in improving gait for older breast cancer survivors who received taxane and/or platinum chemotherapy.

Key Dates

First listed
Oct 8, 2026
Start date
Sep 30, 2026
Status verified
Oct 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Arm I: tDCS first, followed by sham
    Patients receive tDCS, over 20 minutes. One week later patients crossover to receive sham
  • Experimental: Arm II (sham tDCS followed by tDCS)
    Patients receive sham tDCS, over 20 minutes. One week later patients crossover to receive treatment with actual tDCS

Primary Outcome Measure

Dual task gait speed cost [ Time Frame: Before and after stimulation at visit 2 and 3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109
Brendan L. McNeish (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Rogel Cancer Center· Ann Arbor, MI

Related Studies